drugset / Trial / NCT00159679

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159679 ↗

Phase 4 Completed 167 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.

Timeline

Start
2004-09
Primary completion
—
Completion
2005-10

Outcome

Met primary endpoint

paper Pregabalin-treated patients had lower MPS than controls (mean difference, -1.28; p <.001). PMID 18796160 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 600 mg —

Indications